Ask for a checkup package at a private hospital in Shanghai, Beijing or Shenzhen and you will be handed a sheet of tumour marker blood tests: CA-125, CEA, AFP, CA 19-9, CA 15-3, PSA and often a dozen more. They are cheap to add and they produce a tidy row of numbers. They are also the most misunderstood line on a Chinese checkup report. Here is what tumour marker blood tests in China can and cannot tell you, and how to read an elevated result calmly.
What tumour markers actually measure
A tumour marker is a protein or hormone that certain cells release into the bloodstream. Some are produced by cancer cells, but most are also produced by healthy tissue: CEA by normal gut lining, CA-125 by the lining of the uterus, ovaries and peritoneum, AFP by the liver. That overlap is the whole problem. A marker is a signal about cell activity, not a label that says cancer.
A marker result is not a diagnosis
No test on this panel diagnoses cancer on its own. A marker can sit above the reference range with nothing malignant going on, and it can sit inside the range while a tumour is present. Doctors treat markers as one clue among several, alongside imaging, examination and history, usually in people who already have a reason to be tested.
A normal result does not rule cancer out
A meaningful share of early ovarian cancers do not raise CA-125, some pancreatic cancers do not raise CA 19-9, and colon cancer can be present with a perfectly normal CEA. A normal panel is not a clean bill of health, and it should never replace the tests that genuinely change outcomes: colonoscopy, mammography, cervical screening, or low-dose CT for heavy smokers.
Why Chinese checkup packages include so many markers
If you have had checkups in Europe or North America, the size of a Chinese marker panel can be startling. There are two honest reasons, and neither is sinister.
Cultural and clinical habit
China carries a high burden of hepatitis B and, with it, a high rate of liver cancer. Screening with AFP plus liver ultrasound in hepatitis B carriers is genuine, established practice here. That habit spread outward into a checkup culture where an annual full-body screen is the norm and a cheap blood test feels irresponsible to decline.
Commercial logic
Marker assays are inexpensive to run in bulk and easy to market as a comprehensive package. Adding ten of them makes a package look thorough without adding much cost to the hospital. That is not a reason to refuse them — it is a reason to understand what you are buying. Our China medical cost comparison explains why the same panel costs different amounts in different cities.
How to read an elevated marker
An elevated marker is common and usually benign. The question is never simply whether this is cancer. It is what else could explain the number, and what is the safest cheap way to find out.
Benign causes of a raised result
CA-125 rises with menstruation, pregnancy, endometriosis, fibroids, pelvic infection and liver cirrhosis. CEA rises with smoking, COPD, inflammatory bowel disease and liver disease. CA 19-9 rises with gallstones and pancreatitis. AFP is elevated in hepatitis and cirrhosis. PSA rises with benign prostate enlargement, prostatitis, recent ejaculation, or a long bike ride. Age, medication and recent illness move these numbers too.
Repeat first, then image
The usual first step is a repeat test after a few weeks, with the obvious confounders removed, reading the trend rather than the single value. A marker that falls back on its own is reassuring. One that climbs on repeat, or is markedly high from the outset, is a reasonable reason to order targeted imaging. Panic-driven whole-body scanning tends to produce incidental findings, more tests and more anxiety without answering the original question. Our case studies show how these situations are worked through in practice.
Which markers actually have a screening role
Three uses are established enough to state plainly. The rest of a broad panel is information, not screening.
PSA for prostate risk discussion
PSA is the one marker widely used in men with no symptoms, and it works best as the start of a conversation with a doctor rather than as a verdict. Men with a family history of prostate cancer may reasonably discuss testing earlier. What matters is the level and how it changes over time.
AFP with ultrasound in hepatitis B carriers
For people living with chronic hepatitis B — a large group in China — periodic AFP testing combined with liver ultrasound is standard surveillance, usually every six months. It is one of the few marker-plus-imaging combinations that finds liver cancer at a treatable stage in a defined high-risk group. If you carry hepatitis B, keep this up.
CA-125 with ultrasound for specific risk factors
For women with a strong family history of ovarian cancer, a known BRCA mutation, or symptoms that warrant investigation, CA-125 alongside transvaginal ultrasound is a reasonable pathway. For average-risk women with no symptoms it is not recommended as routine screening, because the false-positive rate leads to surgery that turns out to be unnecessary.
A matched panel versus a shotgun panel
The difference between a good checkup and an expensive one is rarely the number of tests. It is whether each test was chosen for you.
Match markers to your risk profile
Age, sex, smoking history, alcohol use, family history, hepatitis status and current symptoms should drive the list. A 34-year-old non-smoking woman with no family history does not need the same panel as a 58-year-old man who smokes and whose father had colon cancer. Markers can still be included, but they should earn their place, and the tests that change outcomes should not be squeezed out by a long marker list.
Ask what a result would change
A useful filter: if this number comes back abnormal, what will we do differently? If the answer is another blood test in three months, indefinitely, the test is probably not earning its cost.
Follow-up logic: who decides, and when to stop
Marker follow-up goes wrong in one of two directions: ignoring a clearly abnormal trend, or chasing a mildly abnormal number for years.
Agree the plan before the first retest
Before you repeat a marker, agree out loud what the next step is for each likely outcome. If it normalises, we stop. If it is unchanged, we image once. If it rises, we refer. A plan fixed in advance prevents the cascade of repeat tests that ends in a scan nobody needed.
Bring an interpreter and your history
Inside a Chinese hospital you move between departments quickly, and a flagged marker is often handled by whoever ordered it. Bring your medical history, any previous results from other countries, and someone who can explain them in Chinese. Our medical visa checklist for China covers the paperwork.
What to do next
Send us your situation
HealthBridge plans health checkups for foreigners in China. Tell us your age, sex, medical history, family history, which city you are in and what you want answered — we build a panel matched to your risk instead of a standard package, and match you to a hospital with English-speaking staff. If you have already had an elevated marker, send us the numbers and the dates and we will tell you what we would do next. Contact us for a checkup plan.